Compare Novartis AG (NVS) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Novartis AG trades at $143.32 (market cap $268.57B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.82 (market cap $47.61B). The key difference: Novartis AG is far larger — about 5.6× iShares 20 Plus Year Treasury Bond ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| NVS | TLT | |
|---|---|---|
Market Cap | $268.57B | $47.61B |
Volume | 1,532,573 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $92.06 |
52-Week Low | $121.80 | $77.11 |
Typical Hold Time | 82 Days | 83 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.71 with a slight 0.73% daily gain amid a challenging bond market environment. The technical picture remains bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights Treasury yields reaching multi-decade highs, with the fund down 11% year-to-date and 46% over five years as investors face a new era of higher interest rates.
The outlook for TLT remains pressured by rising interest rates and inflation concerns, though current yields near 5.3% offer attractive income potential. Key risks include further Fed tightening and economic uncertainty, while potential catalysts could emerge from any moderation in inflation or economic slowdown that might prompt rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
